Literature DB >> 12101288

Comparative evaluation of Mycobacterium vaccae as a surrogate cloning host for use in the study of mycobacterial genetics.

Marco A Medeiros1, Odir A Dellagostin2, Geraldo R G Armôa1, Wim M Degrave3, Leila de Mendonça-Lima3, Márcia Q Lopes3, Joseane F Costa3, Johnjoe Mcfadden4, Douglas McIntosh1.   

Abstract

Mycobacterium vaccae represents an alternative mycobacterial cloning host that has been largely overlooked to date. The main reason for this may be the reported non-transformability of this species, specifically the so-called Stanford strain (NCTC 11659), with expression vectors that use kanamycin resistance as a selection method. However, this strain can be transformed using hygromycin resistance as an alternative selectable phenotype. The present study has shown that in contrast to previous reports, M. vaccae (ATCC 15483) is capable of being transformed with a range of vectors encoding kanamycin resistance as the selectable marker. Thereafter, the expression of the lacZ reporter gene in M. vaccae, Mycobacterium bovis BCG and Mycobacterium smegmatis mc(2)155 was evaluated using a range of characterized mycobacterial promoter sequences (hsp60, hsp70, PAN, 18kDa and 16S rRNA) cloned in the same promoter probe vector. In general, the promoters showed similar levels of activity in the three species, demonstrating that existing expression systems can readily be employed with M. vaccae (ATCC 15483). This was further confirmed by the observation that M. vaccae was capable of stable, in vitro expression of recombinant S1 subunit of pertussis toxin at levels equivalent to those obtained with BCG and M. smegmatis. Analysis of structural and functional stability of a range of vectors demonstrated that the incidence of instability noted for M. vaccae was lower than that recorded for M. smegmatis. Taken together, the results indicate that M. vaccae is an additional cloning host which may prove useful for specific aspects of mycobacterial biology and provide increased flexibility to the field of recombinant protein technology for mycobacteria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101288     DOI: 10.1099/00221287-148-7-1999

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  6 in total

Review 1.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

2.  Transferable, multiple antibiotic and mercury resistance in Atlantic Canadian isolates of Aeromonas salmonicida subsp. salmonicida is associated with carriage of an IncA/C plasmid similar to the Salmonella enterica plasmid pSN254.

Authors:  Douglas McIntosh; Michelle Cunningham; Baijing Ji; Frank A Fekete; Erin M Parry; Sarah E Clark; Zachary B Zalinger; Ilana C Gilg; G Russell Danner; Keith A Johnson; Mike Beattie; Rachael Ritchie
Journal:  J Antimicrob Chemother       Date:  2008-03-28       Impact factor: 5.790

3.  The development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T.

Authors:  Hyungki Lee; Byoung-Jun Kim; Bo-Ram Kim; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

4.  Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.

Authors:  Aakash Mahant; Narcís Saubi; Yoshiki Eto; Núria Guitart; Josep Ma Gatell; Tomáš Hanke; Joan Joseph
Journal:  Hum Vaccin Immunother       Date:  2017-04-20       Impact factor: 3.452

5.  MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice.

Authors:  Esther Broset; Narcís Saubi; Núria Guitart; Nacho Aguilo; Santiago Uranga; Athina Kilpeläinen; Yoshiki Eto; Tomáš Hanke; Jesús Gonzalo-Asensio; Carlos Martín; Joan Joseph-Munné
Journal:  Mol Ther Methods Clin Dev       Date:  2019-02-07       Impact factor: 6.698

6.  Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.

Authors:  Byoung-Jun Kim; Bo-Ram Kim; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  Front Immunol       Date:  2018-03-27       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.